ArticleScientific reports2025
Systemic inflammation accelerates the development of focal segmental glomerulosclerosis in a mouse model of adriamycin induced nephrosis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Recent key advances in the understanding of the pathogenesis of childhood minimal change disease.Childhood kidney diseases · 2026Review
- Inhibiting the P2X7R-NLRP3 inflammasome pathway regulates CXCL16 to alleviate podocyte injury in mice with adriamycin nephropathy.Scientific reports · 2026Article
- Podocyte specific exon skipping after disease onset improves kidney pathology and function in a mouse model of Alport syndrome.Scientific reports · 2025Article
- Multiscale Imaging of Human Adipose Tissue: A Neglected Partner in Proteinuria Linked to Obesity.Biomedicines · 2025Review
- Ultrasound-guided intrarenal arterial injection promotes homing of MSCs and recovery of kidney in Adriamycin-induced nephropathy in rats.Cell transplantationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Research indicates that minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS) may reflect varying severities of the same underlying condition, with inflammation potentially facilitating the progression from MCD to FSGS. The aim of this study was to determine the whether systemic inflammation accelerated the progression from MCD to FSGS in a mouse model of Adriamycin-induced nephrosis. In this model, systemic inflammation induced transient proteinuria without significant serum biochemical alterations or significant renal histological changes in control mice that did not develop nephrotic syndrome. In contrast, both mice with Adriamycin-induced nephrosis mice and mice with Adriamycin-induced nephrosis with systemic inflammation showed histological features of MCD at week 4 and progressive exacerbation of FSGS. However, the glomerular lesions of mice with Adriamycin-induced nephrosis in a state of systemic inflammation were more obvious than those of mice with Adriamycin-induced nephrosis. These findings suggest that systemic inflammation may hasten histological development from MCD to FSGS in this mouse model.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.